<?xml version="1.0" encoding="UTF-8" standalone="yes"?><rss version="2.0">    <channel>        <title>GSK news</title>        <link>http://www.gsk.com/media/index.htm</link>        <description>GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.</description>                    <item>                <title>GlaxoSmithKline to fully acquire Cellzome for £61 million</title>                                    <description><![CDATA[GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.]]></description>                                <pubDate>Tue, 15 May 2012 09:03:54 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1090550.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1090550.htm</guid>                            </item>                    <item>                <title>GSK statement on BBC Panorama broadcast: ‘the truth about tax’</title>                                    <description><![CDATA[GSK statement on BBC Panorama broadcast: ‘the truth about tax’]]></description>                                <pubDate>Mon, 14 May 2012 20:10:00 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1089491.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1089491.htm</guid>                            </item>                    <item>                <title>Stiefel receives US FDA approval of Fabior™ Foam, 0.1%</title>                                    <description><![CDATA[Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.]]></description>                                <pubDate>Fri, 11 May 2012 23:08:25 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1086739.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1086739.htm</guid>                            </item>                    <item>                <title>GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash</title>                                    <description><![CDATA[GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash]]></description>                                <pubDate>Thu, 10 May 2012 11:55:27 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1083714.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1083714.htm</guid>                            </item>                    <item>                <title>GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash</title>                                    <description><![CDATA[GSK announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.  ]]></description>                                <pubDate>Wed, 09 May 2012 06:36:50 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1081156.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1081156.htm</guid>                            </item>                    <item>                <title>James Shannon named GlaxoSmithKline Chief Medical Officer</title>                                    <description><![CDATA[James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1 May.  James will report to R&D Chairman Moncef Slaoui and be based in London.  He will be accountable for medical governance and patient safety for all of GSK: Pharmaceuticals, Consumer Healthcare, Vaccines and the global businesses.]]></description>                                <pubDate>Fri, 04 May 2012 09:28:09 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1074979.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1074979.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline plc appoints two Non-Executive Directors to its Board</title>                                    <description><![CDATA[GlaxoSmithKline plc appoints two Non-Executive Directors to its Board]]></description>                                <pubDate>Thu, 03 May 2012 12:39:24 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1073681.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1073681.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines</title>                                    <description><![CDATA[GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines]]></description>                                <pubDate>Tue, 01 May 2012 12:40:54 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1070641.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1070641.htm</guid>                            </item>                    <item>                <title>GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)</title>                                    <description><![CDATA[GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)]]></description>                                <pubDate>Fri, 27 Apr 2012 12:04:47 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1066368.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1066368.htm</guid>                            </item>                    <item>                <title>FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma</title>                                    <description><![CDATA[GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy.]]></description>                                <pubDate>Thu, 26 Apr 2012 22:21:55 GMT</pubDate>                                    <link>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1064988.htm</link>                    <guid>http://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1064988.htm</guid>                            </item>            </channel></rss>
